YAP1 and neoplasm: By a CCK8 assay, colony formation assay, and flow cytometry, our team is the first to develop the strategy of co-targeting YAP1 and PD-L1 in SCLC, which dramatically boosted anti-tumor immunity and provided new ideas for combination therapy in patients with the SCLC-Y subtype.